From analytical similarity to clinical confidence: how regulatory evolution ensures comparable immunogenicity in streamlined biosimilar development. [PDF]
Ribes S +4 more
europepmc +1 more source
Demonstrating interchangeability and biosimilarity for US biosimilars [PDF]
openaire +1 more source
Complement inhibitor therapy in atypical hemolytic uremic syndrome (aHUS): evaluating the economic impact of introducing eculizumab biosimilars in Germany. [PDF]
Kaufhold I +4 more
europepmc +1 more source
Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union. [PDF]
Aithal R +4 more
europepmc +1 more source
BIOSIMILARS IN ONCOLOGY – PART I: THE PRINCIPLES OF BIOSIMILARS
Moorkens, Evelien +4 more
openaire +2 more sources
Safety and Efficacy of Adalimumab Biosimilar in Psoriasis and Hidradenitis Suppurativa: <i>A Clinical Experience</i>. [PDF]
Najjar RH +5 more
europepmc +1 more source
Evidence for the use of anti-CD20 therapeutic antibodies in immune thrombotic thrombocytopenic purpura management: a review. [PDF]
Halkidis K, Meng C, Snyder J.
europepmc +1 more source
Safety and effectiveness of rituximab biosimilar (Rituximab-GP2013) versus originator in rheumatoid arthritis: real-world evidence from a single center. [PDF]
Bayeh B +16 more
europepmc +1 more source
Clinical and Cost-Effectiveness of Omalizumab in Concomitant Asthma and Chronic Rhinosinusitis with Nasal Polyps: A Real-World Exploratory Study. [PDF]
Xu X +7 more
europepmc +1 more source

